Puma Biotechnology | PBYI - Assets


Puma Biotechnology reported $202.86M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
Exelixis USD 2.84B 20.87M Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Glaxosmithkline GBP 82.45B 23.19B Sep/2025
Incyte USD 6.96B 627.62M Dec/2025
MacroGenics USD 270.76M 25.34M Sep/2025
Moderna USD 12.34B 203M Dec/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
Takeda JPY 15.41T 938.47B Dec/2025
TG Therapeutics USD 1.06B 38.23M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025